Due to the ongoing global pandemic Covid-19, ESO and ESMO have taken the decision to convert the ESO-ESMO Baltic and Eurasia Masterclass in Clinical Oncology that was scheduled in 7-11 July 2021, into virtual ON-LINE MASTERCLASS.
We have done our best to design and build a new programme keeping the interactive, international, and collaborative Masterclass spirit which will include pre-recorded lectures, live sessions, clinical case presentations and direct contact with the Faculty members.
The online edition will be divided into two parts:
PART 1 (available from 10 June 2021)
Pre-recorded lectures will be organized into Modules based on tumour type and made available for participants to view in their own time one month before part 2. On completion of each module, participants will be given the opportunity to send questions related to the lectures, that will then be answered Live by the Faculty during part 2.
All modules from part 1 must be completed before part 2.
PART 2 (10-11 July 2021)
Online live event with lectures/ live discussion and participants’ case presentations to be discussed with top level experts. Selected participants will be paired and asked to prepare a clinical case together with a colleague from a different Country/Hospital.
Masterclass coordinator: N. Pavlidis, GR
ESO Chair: F. Peccatori, IT
ESMO Chair: F. Lordick, DE
Host Chair: A. Elme, EE
The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic development. State-of-the-art data recognised by ESMO and other evidence-based guidelines will be cited. Participants will deliver case presentations within tumour board basis and discuss them with the chairs and the faculty. Additional time will be allocated for participants to deliver case presentations within small groups and receive feedback.
As for all Masterclasses, the number of participants will be limited and admission will be by competitive application only.
All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.
AIMS AND OBJECTIVES
This clinically oriented educational programme is designed for medical, clinical and radiation oncologists who wish to improve their skills in multidisciplinary care management.
The programme will expose participants to a full spectrum of issues in clinical oncology and practice-orientated training focusing on lung, genito-urinary, breast, head-and-neck, gastrointestinal, gynaecological cancers. Spotlight sessions will facilitate compact update on different topics (programme will be published soon).
THE MASTERCLASS IS
• Full immersion
• An international faculty of top experts delivering lectures focusing on lung, genito-urinary, breast, head-and-neck, gastrointestinal and gynaecological cancers.
In this review, the authors summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. The MCO has become a major educational event of ESO, intending to educate young oncologists from various countries within or outside Europe, providing an up-to-date interactive program based on solid evidence for all presented topics.
"Reprinted from Critical Reviews in Oncology / Hematology, Pavlidis et al, Copyright (2019)
https://doi.org/10.1016/j.critrevonc.2019.07.022 with permission from Elsevier”
• Download PDF document
Detailed list of invited speakers will be available soon.
European School of Oncology (ESO)
Via Turati 29 - 20121 Milan, Italy
Tel: +39 02 85464529
Fax: +39 02 85464545
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE). The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.
Application for CME recognition will be submitted to the European Society for Medical Oncology (ESMO) for ESMO-MORA accreditation. Further information will follow.
Use the hashtag #ESOexperience and follow us on Facebook, Twitter and Instagram: @esoncology
Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enrol in ESCO - the College of the European School of Oncology.
A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.esco.org for information on how to join ESCO.
In the event of registrations to events held in partnership with other entities (clearly specified in the title of the event or by sending a request to ESO), please be aware that the partner should be considered joint data controller and that the consents provided to ESO will be transferred to the partner as well. Any subsequent consent modifications will need to be communicated to the partner directly.
|Application deadline:||20 March 2021|
|Save event date:||07 July 2021|
|Early registration by:||insert the date|
|Late registration by:||insert the date|
|Onsite registration from:||insert the date|
PARTICIPANT’S PROFILE OF THE MASTERCLASS CANDIDATE
• Age up to 40 years
• At least 2-3 years’ experience in medical or clinical oncology
• This event is designed to meet the educational needs of participants practicing in Baltic and Eurasian countries.
• Involvement in scientific activities
• Intermediate level of English
HOW TO APPLY
Interested oncologists should apply online (at the top of this page) providing:
• Letter describing motivation for attending;
• Supporting letter from head of department or mentor;
• CV with list publications (if the list of publications is not provided, it will be assumed that no articles have been
• Clinical case (see below)
Priority will be given to applicants practicing in Baltic and Eurasian countries.
CLINICAL CASE PRESENTATION
Submit an abstract of one page on the template (form available at the bottom of this page), describing a clinical case related to one of the subjects of the Masterclass (lung, genitourinary, breast, head-and-neck, gastrointestinal and gynaecological cancers). You will have to present your case at the Masterclass in format of a clinical grand round discussion. Please provide straightforward a case of your daily clinical practice - no uncommon or extremely rare cases. A maximum of 10 slides will be permitted containing:
• Diagnostic considerations
• Results, follow-up
• At least three questions proposed for discussion with the faculty
Participants will be asked to bring their personal laptop or tablet (wireless enabled) to the Masterclass as an event dedicated website will be created and all questionnaires and certificates will be accessible only from there. Any potential problems with meeting this request should be communicated to the secretariat as part of the application process.
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration and half board accommodation
APPLICATION DEADLINE: 30 MARCH 2021
Before you start completing the online application form, please be sure you have all the requested files (CV, Motivation letter, Supporting letter, Professional experience template and Abstract template) ready to be uploaded to the system. Online applications will not be complete unless all the files are uploaded.
• Download HERE your Professional experience template
• Download HERE your Abstract template
Part 1 Programme:
Part 1 has 6 blocks:
Block 1) Breast cancer
• Current controversies and challenges in breast cancer surgery – MJ Cardoso, PT
• Systemic treatment of early and advanced triple negative disease – G. Curigliano, IT
• Systemic treatment of HER2+ early and advanced disease – A. Eniu, CH
• Current controversies and challenges in radiotherapy – F. Geara, LB
• Preoperative chemotherapy and biologicals – N. Harbeck, DE
• Systemic treatment of luminal early and advanced breast cancer – O. Pagani, CH
• Molecular diagnostic pathology – G. Pruneri, IT
• Optimal approach in locally advanced disease: ESO-ESMO ABC Guidelines – F. Cardoso, PT
Block 2) Lung cancer
• Multimodality treatment of stage III NSCLC – R. Dziadziuszko, PL
• Molecular diagnostic pathology of NSCLC – I. Kern, SI
• Radiotherapy for NSCLC – F. Mc Donald, UK
• Systemic therapy for NSCLC with oncogenic driver mutations – C. Rolfo, US
• Systemic therapy for NSCLC without oncogenic driver mutations – S. Peters, CH
• Multimodality treatment of SCLC – R. Stahel, CH
• Surgery for early and locally advanced NSCLC – I. Schmitt-Opitz, CH
Block 3) Gastro-intestinal cancer
• Multimodal management of localized rectal cancer – A. Cervantes, ES
• Management of pancreatic cancer – S. De Dosso, CH
• Systemic treatment in advanced oesophageal and gastric cancer – F. Lordick, DE
• Adjuvant treatment in colon cancer – D. Papamichael, CY
• Liquid biopsies in GI tumors – F. Penault-Llorca, FR
• Optimal sequencing of systemic treatment for advanced hepatocellular carcinoma – A. Vogel, DE
• Systemic treatment in advanced colorectal cancer – E. van Cutsem, BE
Block 4) Gynaecological cancer
• Systemic treatment in cervical and endometrial cancer – C. Sessa, CH
• Systemic management of ovarian cancer and inhibitors of Parp – J.B. Vermorken, BE
• Guidelines in endometrial cancer – N. Colombo, IT
Block 5) Genitourinary cancer
• Management of testicular cancer – J. Beyer, CH
• First line endocrine therapy in endocrine sensitive prostate cancer – K. Fizazi, FR
• Localized prostate cancer – J. Khader, JO
• Systemic treatment of bladder cancer – H. Khaled, EG
• Treatment of endocrine resistant and refractory prostate cancer – X. Maldonado, ES
• Metastatic renal cancer: evidence-based treatment – N. Mottet, FR
Block 6) Spotlights
• Communication skills – F. Boyle, AU
• Ethics issues – S. Hurst-Majno, CH
• Breast cancer during pregnancy and fertility preservation – F.A. Peccatori, IT
• Early integration in oncology, supportive and palliative care – S. Peters, CH
• Cancer patients with COVID-19 – M. Garassino, IT
• Nutrition – J. Arends, DE
• Genomic Tests in clinical practice – F. Cardoso, PT
• Cancer in the elderly – M. Aapro, CH
• Immuno-oncology – H.A. Azim Jr., MX
• Parp inhibitors in BRCA mutation carriers – G. Curigliano
Information on PART 2 (live weekend on 10-11 July) will follow soon.